The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Nociceptin/Orphanin FQ (N/OFQ) is a 17 amino acid peptide that was deorphanized in 1995. The generation of specific agonists, antagonists and receptor deficient mice and rats has enabled progress in elucidating the biological functions of nociceptin. In addition, radio-imaging technologies have been advanced for investigation of this system in animals and humans. Together with traditional neurobehavioral techniques, these tools have been utilized to identify the biological significance of the N/OFQ system and its interacting partners. The present commentary focuses on the role of N/OFQ in the regulation of feeding and body weight homeostasis, stress and the stress-related psychiatric disorders of depression and anxiety, and in drug and alcohol dependence. Critical evaluation of the current scientific preclinical literature suggests that small molecule modulators of nociceptin opioid peptide receptors (NOP) might be useful in the treatment of diseases related to these biological functions. In particular, the literature data suggest that antagonism of NOP receptors will produce anti-obesity and antidepressant activities in humans. However, there are also contradictory data discussed. The current literature on the role of N/OFQ in anxiety and addiction, on the other hand points primarily to a role of agonist modulation being potentially therapeutic. Some drug-like molecules that function either as agonists or antagonists of NOP receptors have been optimized for human clinical study to test some of these hypotheses. The discovery of PET ligands for NOP receptors, combined with the pharmacological tools and burgeoning preclinical data set discussed here bodes well for a rapid advancement of clinical understanding and potential therapeutic benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The neural basis of drug craving: An incentive-sensitization theory of addiction
Robinson, T. (1993) · Brain Research Reviews · doi:10.1016/0165-0173(93)90013-p · Cited by 7,346
Neurocircuitry of stress: central control of the hypothalamo–pituitary–adrenocortical axis
Herman, J. P., & Cullinan, W. E. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10069-2 · Cited by 2,270
Wise, R. A., & Rompre, P.-P. (1989) · Annual Review of Psychology · doi:10.1146/annurev.ps.40.020189.001203 · Cited by 1,968
Opioids excite dopamine neurons by hyperpolarization of local interneurons
Johnson, S., & North, R. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-02-00483.1992 · Cited by 1,637
Buprenorphine Treatment of Refractory Depression
Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502000-00008 · Cited by 346 · cited 1×
“Several small open-label and controlled clinical studies have demonstrated that the mixed opiate pharmacology compound buprenorphine exhibits rapid onset antidepressant activity in patients with treatment refractory depression (Emrich et al. 1982; Bodkin et al. 1995; Pharmacol Ther.”
BackgroundGreenwald, M. K., Johanson, C.-E., Moody, D. E., Woods, J. H., Kilbourn, M. R., Koeppe, R. A., Schuster, C. R., & Zubieta, J.-K. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300251 · Cited by 320
A systematic review of variables associated with the relationship between obesity and depression.
Preiss, K., Brennan, L., & Clarke, D. (2013) · Obesity Reviews · doi:10.1111/obr.12052 · Cited by 285
The Mechanistic Classification of Addictive Drugs
Lüscher, C., & Ungless, M. A. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030437 · Cited by 255
Lutfy, K., Eitan, S., Bryant, C. D., Yang, Y. C., Saliminejad, N., Walwyn, W., Kieffer, B. L., Takeshima, H., Carroll, F. I., Maidment, N. T., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-32-10331.2003 · Cited by 211
Economidou, D., Hansson, A. C., Weiss, F., Terasmaa, A., Sommer, W. H., Cippitelli, A., Fedeli, A., Martin-Fardon, R., Massi, M., Ciccocioppo, R., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.02.004 · Cited by 120
Self-citationMartin-Fardon, R., Zorrilla, E. P., Ciccocioppo, R., & Weiss, F. (2010) · Brain Research · doi:10.1016/j.brainres.2009.12.027 · Cited by 112 · cited 6×
“In fact, Wistar rats made dependent on ethanol and then tested for ethanol self-administration 1 week following withdrawal, were sensitive to the suppressant effects and to the anxiolytic-like action of N/OFQ whereas nondependent controls rats remained less sensitive (Economidou et al., 2011; Martin-Fardon et al., 201…”
BackgroundInfluentialSelf-citationDepressive symptoms during buprenorphine treatment of opioid abusers
Kosten, T. R., Morgan, C., & Kosten, T. A. (1990) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(90)90035-o · Cited by 110
Chen, S. A., O'Dell, L. E., Hoefer, M. E., Greenwell, T. N., Zorrilla, E. P., & Koob, G. F. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301008 · Cited by 97 · cited 1×
“Preclinical studies evaluating the efficacy of buprenorphine against opioid self-administration have been mixed, with some studies indicating suppression of heroin self-administration (Mello et al. 1983; Chen et al. 2006), while others show no effect (Sorge and Stewart 2006).”
BackgroundComparison of buprenorphine and methadone effects on opiate self-administration in primates
Mello, N. K., Bree, M. P., & Mendelson, J. H. (1983) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33600-1 · Cited by 85
Genetic Markers of Comorbid Depression and Alcoholism in Women
Procopio, D. O., Saba, L. M., Walter, H., Lesch, O., Skala, K., Schlaff, G., Vanderlinden, L., Clapp, P., Hoffman, P. L., & Tabakoff, B. (2013) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12060 · Cited by 52 · cited 1×
“In addition, MDD and obese patients also have a high prevalence of alcohol abuse disorder and abuse (c.f., Procopio et al., 2013).”
Background
Cited by
Advances in the science and treatment of alcohol use disorder
Witkiewitz, K., Litten, R. Z., & Leggio, L. (2019) · Science Advances · doi:10.1126/sciadv.aax4043 · Cited by 592
Opioid receptors: drivers to addiction?
Darcq, E., & Kieffer, B. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0028-x · Cited by 352
Toll, L., Bruchas, M. R., Calo', G., Cox, B. M., & Zaveri, N. T. (2016) · Pharmacological Reviews · doi:10.1124/pr.114.009209 · Cited by 297
The Neuropeptide Tac2 Controls a Distributed Brain State Induced by Chronic Social Isolation Stress
Zelikowsky, M., Hui, M., Karigo, T., Choe, A., Yang, B., Blanco, M. R., Beadle, K., Gradinaru, V., Deverman, B. E., & Anderson, D. J. (2018) · Cell · doi:10.1016/j.cell.2018.03.037 · Cited by 286
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
Metadata
- Authors
- Witkin, J. M., Statnick, M. A., Rorick-Kehn, L. M., Pintar, J. E., Ansonoff, M., Chen, Y., Tucker, R. C., & Ciccocioppo, R.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 141
- Issue
- 3
- Pages
- 283-299
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2002153331
- Cited by
- 194
- References
- 15
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.